According to consensus at the National Heart, Lung and Blood Institutes (NHLBI) workshop, Bronchopulmonary Dysplasia (BPD) is defined as the need for increased oxygen in infants: 28 d or at discharge (whichever comes first). It applied the clinical criteria from both 28 days of oxygen need and an assessment of respiratory support at 36 weeks’ postmenstrual age (PMA).
The definition of BPD has evolved throughout the years. The new BPD includes the total duration of oxygen supplementation, positive pressure requirements, and gestational age, in addition to oxygen dependency at 36 weeks. The definition allows the severity of the disease to be classified into mild, moderate, and severe form, by oxygen dependency and respiratory support at 36 weeks’ PMA.
Get FREE sample copy at:
The Bronchopulmonary Dysplasia market report also covers emerging drugs, current treatment practices, Bronchopulmonary Dysplasia market share of the individual therapies, current and forecasted Bronchopulmonary Dysplasia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Bronchopulmonary Dysplasia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Bronchopulmonary Dysplasia Market Key Facts
As per DelveInsight estimates, the total cases of Bronchopulmonary Dysplasia (BPD) in the 7MM was found to be 64,468 in 2017. Among all the countries, the estimates show a higher population of BPD in the United States in 2017.
Among the European 5 countries, the UK had the highest cases of BPD with 13,889 cases, followed by Spain and France, in 2017. On the other hand, Italy had the lowest cases in 2017. As per our estimates, Japan had 6,968 cases of BPD in 2017.
The occurrence of BPD has considerably upturned in the past few decades, due to increased preterm birth cases and their improved survival rates of very low birth infants with support of mechanical ventilation.
On the basis of severity, the BPD has been classified as the mild, moderate and severe cases, where the maximum number of cases were found to be that of severe BPD in 7MM, followed by mild and moderate.
Key Benefits of Bronchopulmonary Dysplasia Market Report
Bronchopulmonary Dysplasia market report provides an in-depth analysis of Bronchopulmonary Dysplasia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Bronchopulmonary Dysplasia market report will help in developing business strategies by understanding the Bronchopulmonary Dysplasia Market trends & developments, key players and future market competition that will shape and drive the Bronchopulmonary Dysplasia market in the upcoming years.
The Bronchopulmonary Dysplasia market report covers Bronchopulmonary Dysplasia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Bronchopulmonary Dysplasia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Owing to the launch of upcoming therapies, the Market Size of Bronchopulmonary Dysplasia shall increase during the forecast period.
The Bronchopulmonary Dysplasia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Bronchopulmonary Dysplasia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Bronchopulmonary Dysplasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Bronchopulmonary Dysplasia Epidemiology
The Bronchopulmonary Dysplasia epidemiology section covers insights about historical and current Bronchopulmonary Dysplasia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Bronchopulmonary Dysplasia Drugs Uptake and Key Market Players
The Bronchopulmonary Dysplasia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched in the market during the study period. The analysis covers Bronchopulmonary Dysplasia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies in the Bronchopulmonary Dysplasia market include:
Bronchopulmonary Dysplasia Therapies Covered:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Bronchopulmonary Dysplasia Competitive Intelligence Analysis
4. Bronchopulmonary Dysplasia Market Overview at a Glance
5. Bronchopulmonary Dysplasia Disease Background and Overview
6. Bronchopulmonary Dysplasia Patient Journey
7. Bronchopulmonary Dysplasia Epidemiology and Patient Population
8. Bronchopulmonary Dysplasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Bronchopulmonary Dysplasia Unmet Needs
10. Key Endpoints of Bronchopulmonary Dysplasia Treatment
11. Bronchopulmonary Dysplasia Marketed Products
12. Bronchopulmonary Dysplasia Emerging Therapies
13. Bronchopulmonary Dysplasia Seven Major Market Analysis
14. Attribute Analysis
15. Bronchopulmonary Dysplasia Market Outlook (7 major markets)
16. Bronchopulmonary Dysplasia Access and Reimbursement Overview
17. KOL Views on the Bronchopulmonary Dysplasia Market.
18. Bronchopulmonary Dysplasia Market Drivers
19. Bronchopulmonary Dysplasia Market Barriers
21. DelveInsight Capabilities
Bronchopulmonary Dysplasia – Epidemiology Forecast to 2030
DelveInsight’s Bronchopulmonary Dysplasia – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Bronchopulmonary Dysplasia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Bronchopulmonary Dysplasia – Pipeline Insights, 2020
Bronchopulmonary Dysplasia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Bronchopulmonary Dysplasia market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd 2432
City: Las Vegas
Country: United States